Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC |
GAGE L PATRICKDirector
|
Exercise / conversionCommon Stock | 5,000 | $4.02 | $20,100.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 19:20 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001061983-17-000053 · edgardoc.xml · derivative · entry 3 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 19:20 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0001061983-17-000053 · edgardoc.xml · nonDerivative · entry 2 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 23, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 19:20 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 5,000 | $4.44 | $22,200.00 |
DisclosureSEC source: 0001061983-17-000053 · edgardoc.xml · nonDerivative · entry 1 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 23, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 695 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 45 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 695 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 44 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,552 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 43 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,552 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 617 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 42 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 617 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,206 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 41 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 15,206 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,666 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 40 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,517 Underlying: Common Stock · 16,666 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,079 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 39 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,079 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,795 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 38 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,795 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,638 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 37 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,638 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 36 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,448 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 35 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 13,448 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,883 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 34 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,883 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,294 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 33 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 2,294 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,920 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 32 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,920 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 21,204 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 31 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,204 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 2,638 | $15.00 | $39,570.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 30 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 2,638 | $11.10 | $29,281.80 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 29 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 695 | $15.00 | $10,425.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 28 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 695 | $11.10 | $7,714.50 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 27 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 2,639 | $15.00 | $39,585.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 26 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 25 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 694 | $15.00 | $10,410.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 24 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 23 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 11,883 | $15.00 | $178,245.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 22 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 11,883 | $9.42 | $111,937.86 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 21 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 617 | $15.00 | $9,255.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 20 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 617 | $9.42 | $5,812.14 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 19 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 13,920 | $15.00 | $208,800.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 18 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 13,920 | $6.30 | $87,696.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 17 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 1,079 | $15.00 | $16,185.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 16 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 1,079 | $6.30 | $6,797.70 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 15 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 21,204 | $15.00 | $318,060.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 14 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 21,204 | $6.00 | $127,224.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 13 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 3,795 | $15.00 | $56,925.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 12 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 3,795 | $6.00 | $22,770.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 11 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 13,448 | $15.00 | $201,720.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 10 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 13,448 | $9.65 | $129,773.20 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 9 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 11,552 | $15.00 | $173,280.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 8 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 11,552 | $9.65 | $111,476.80 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 7 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 2,294 | $15.00 | $34,410.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 6 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 2,294 | $7.96 | $18,260.24 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 5 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 15,206 | $15.00 | $228,090.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 4 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 15,206 | $7.96 | $121,039.76 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 3 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
SaleCommon Stock | 16,666 | $15.00 | $249,990.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 2 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Exercise / conversionCommon Stock | 16,666 | $6.67 | $111,162.22 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 1 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 19:29 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001061983-17-000049 · edgardoc.xml · derivative · entry 3 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.